$6.95
+0.08 (+1.16%)
Open$6.95
Previous Close$6.87
Day High$6.98
Day Low$6.95
52W High$10.31
52W Low$2.71
Volume—
Avg Volume713.1K
Market Cap290.84M
P/E Ratio3.16
EPS$2.65
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+448.6% upside
Current
$6.95
$6.95
Target
$38.13
$38.13
$23.34
$38.13 avg
$40.06
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 171.58M | 163.07M | 22.23M |
| Net Income | 174.2K | 149.0K | -3,026,461 |
| Profit Margin | 0.1% | 0.1% | -13.6% |
| EBITDA | 136.06M | 122.85M | -4,014,681 |
| Free Cash Flow | — | — | -2,971,274 |
| Rev Growth | +5.2% | +5.2% | +14.5% |
| Debt/Equity | 0.41 | 0.41 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |